Saturday, October 31, 2020
Home Life Style Health & Fitness 'Sputnik V' COVID Vaccine Gets Approval for Clinical Trials in India

‘Sputnik V’ COVID Vaccine Gets Approval for Clinical Trials in India

Russian Vaccine Sputnik V Has Been Approved for Second and Third Phase Testing

The Drug Controller General of India (DCGI) has granted approval to Dr. Reddy’s, a global pharmaceutical company headquartered in India, to conduct phase 2 and 3 clinical human trials of the Sputnik V, a COVID-19 vaccine made by Russia.

On September 16, the Russian Direct Investment Fund (RDIF) and Dr. Reddy’s Laboratories Limited had agreed to cooperate on clinical trials and distribution of the Sputnik V COVID-19 vaccine in India.

Sputnik V, an adenovirus vector-based vaccine, was developed by the Gamaleya Scientific Research Institute of Epidemiology and Microbiology, along with the Russian Direct Investment Fund and registered on August 11.

Follow NewsGram on LinkedIn to know what’s happening around the world.

Co-chairman and Managing Director of Dr. Reddy’s Laboratories G.V. Prasad in a statement said “This is a significant development that allows us to commence the clinical trials in India and we are committed to bringing in a safe and efficacious vaccine to combat the pandemic.”

Sputnik V
The Drug Controller General of India (DCGI) has granted approval to Dr. Reddy’s, a global pharmaceutical company headquartered in India to Sputnik V made by Russia. Pixabay

“On regulatory approval in India, RDIF shall supply to Dr. Reddy’s 100 million doses of the vaccine. The Sputnik V vaccine, which is based on a well-studied human adenoviral vector platform with proven safety, is undergoing clinical trials for the coronavirus pandemic,” a statement from the Russian fund had earlier stated.

Also Read: Scientists Develop New Blood Test to Predict Which Covid-19 Patients at Severe Risk

The Russian Direct Investment Fund had also said that the deliveries could potentially begin in late 2020 subject to completion of successful trials and registration of the vaccine by regulatory authorities in India.

“The agreement between RDIF and Dr. Reddy’s reflects the growing awareness of countries and organizations to have a diversified anti-COVID vaccine portfolio to protect their populations,” RDIF added. (IANS)

STAY CONNECTED

19,120FansLike
362FollowersFollow
1,779FollowersFollow

Most Popular

Menstrual Dysfunction Prevalent in Young Athletes

Researchers, including one of Indian-origin, have found that menstrual dysfunction is more prevalent in young athletes than among non-athletes of a similar age. The study,...

Spinning Keeps You Energized and Your Mind Focused

One of the most popular cardio work-outs in North America, Latin America, Europe, and other parts of Asia, and a current global phenomenon, rhythm-based...

Change in Indian Healthcare Industry is Need of the Hour

With all the chaos created due to the pandemic, a change in the Indian healthcare industry is the need of the hour, feels Anita...

Food Habits to Follow if You Have Arthritis

Arthritis is an autoimmune disease that affects joint and bone pain. It could be a problem or a matter of concern, If not taken...

New Mask Aiming to Make Wearer Less Infectious

People wear face masks to protect others -- not merely to protect themselves. With this in mind, researchers have developed a new concept for...

Cognitive Disorders Increase Risks of Developing Severe COVID

Researchers have claimed that dementia and other cognitive disorders now appear to be the risk factors for developing severe COVID-19. The findings, published in the...

Localized Content Driving New Customers in Amazon Prime Video

Riding on localized content being churned out in countries like India, the number of Prime members who stream Prime Video grew by more than...

Cheerful People Likely to Experience Less Memory Decline

People who feel enthusiastic and cheerful -- what psychologists call "positive affect" -- are less likely to experience memory decline as they age, say...

Recent Comments